Therapy innovation for the treatment of pancreatic neuroendocrine tumors

Bibliography

• Yao JC, Eisner MP, Leary C, Population-based study of islet cell carcinoma. Ann Surg Oncol 2007;14:3492-500
   PubMed Web of Science ®Google Scholar
• Yao JC, Hassan M, Phan A, One hundred years after “Carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008;26:3063-72
   PubMed Web of Science ®Google Scholar
• Yao JC, Lombard-Bohas C, Baudin E, Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol 2010;28:69-76
   PubMed Web of Science ®Google Scholar
• Kloppel G, Perren A, Heitz PU. The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification. Ann NY Acad Sci 2004;1014:13-27
   PubMed Web of Science ®Google Scholar
• Arnold R. Endocrine tumours of the gastrointestinal tract. Introduction: definition, historical aspects, classification, staging, prognosis and therapeutic options. Best Pract Res Clin Gastroenterol 2005;19:491-505
   PubMed Web of Science ®Google Scholar
• Bettini R, Boninsegna L, Mantovani W, Prognostic factors at diagnosis and value of WHO classification in a mono-institutional series of 180 non-functioning pancreatic endocrine tumours. Ann Oncol 2008;19:903-8
   PubMed Web of Science ®Google Scholar
• Halfdanarson TR, Rabe KG, Rubin J, Petersen GM. Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival. Ann Oncol 2008;19:1727-33
   PubMed Web of Science ®Google Scholar
• Rindi G, Kloppel G, Couvelard A, TNM staging of midgut and hindgut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2007;451:757-62
   PubMed Web of Science ®Google Scholar
• Chatzipantelis P, Konstantinou P, Kaklamanos M, The role of cytomorphology and proliferative activity in predicting biologic behavior of pancreatic neuroendocrine tumors: a study by endoscopic ultrasound-guided fine-needle aspiration cytology. Cancer Cytopathol 2009;117:211-16
   PubMed Web of Science ®Google Scholar
• Bosman F, Carneiro F, Hruban R, Theise N. editors. WHO Classification of Tumours of the Digestive System. 4th edition. IARC Press; Lyon, France: 2010
   Google Scholar
• Klimstra DS, Modlin IR, Coppola D, The pathologic classification of neuroendocrine tumors. A review of nomenclature, grading, and staging systems. Pancreas 2010;39:707-12
   PubMed Web of Science ®Google Scholar
• Hill JS, McPhee JT, McDade TP. Zheng Zhou, et al. Pancreatic neuroendocrine tumors the impact of surgical resection on survival. Cancer 2009;115:741-51
   PubMed Web of Science ®Google Scholar
• Knigge U, Hansen CP, Stadil F. Interventional treatment of neuroendocrine liver metastases. Surgeon 2008;6:232-9
   PubMed Web of Science ®Google Scholar
• Yao KA, Talamonti MS, Nemcek A, Indications and results of liver resection and hepatic chemoembolization for metastatic gastrointestinal neuroendocrine tumors. Surgery 2001;130:677-82
   PubMed Web of Science ®Google Scholar
• Kidd M, Modlin IM. Small intestinal neuroendocrine cell pathobiology: ‘carcinoid' tumors. Curr Opin Oncol 2011;23:45-52
   PubMed Web of Science ®Google Scholar
• Burnik FS, Yalcin S. NFKB1-94 insertion/deletion ATTG polymorphism in gastroenteropancreatic neuroendocrine tumors. Chemotherapy 2009;55:381-5
   PubMed Web of Science ®Google Scholar
• Wang Q, Fang WH, Krupinski J, Pax genes in embryogenesis and oncogenesis. J Cell Mol Med 2008;12:2281-94
   PubMed Web of Science ®Google Scholar
• Sosa-Pineda B. The gene Pax4 is an essential regulator of pancreatic betacell development. Mol Cells 2004;18:289-94
   PubMed Web of Science ®Google Scholar
• Long KB, Srivastava A, Hirsch MS, Hornick JL. PAX8 expression in well differentiated pancreatic endocrine tumors: correlation with clinic-pathologic features and comparison with gastrointestinal and pulmonary carcinoid tumors. Am J Surg Pathol 2010;34:723-9
   PubMed Web of Science ®Google Scholar
• Panzuto F, Nasoni S, Falconi M, Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization. Endocr Relat Cancer 2005;12:1083-92
   PubMed Web of Science ®Google Scholar
• Metz DC, Jensen RT. Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology 2008;135:1469-92
   PubMed Web of Science ®Google Scholar
• Casanovas O, Hicklin DJ, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signalling in late-stage pancreatic islet tumors. Cancer Cell 2005;8:299-309
   PubMed Web of Science ®Google Scholar
• Inoue M, Hager JH, Ferrara N, VEGF-A has a critical, non redundant role in angiogenic switching and pancreatic beta cell carcinogenesis. Cancer Cell 2002;1:193-202
   PubMed Web of Science ®Google Scholar
• Fjallskog ML, Lejonklou MH, Oberg KE, Expression of molecular targets for tyrosine kinase receptor antagonists in malignant endocrine pancreatic tumors. Clin Cancer Res 2003;9:1469-73
   PubMed Web of Science ®Google Scholar
• Fjallskog ML, Hessman O, Eriksson B, Janson ET. Upregulated expression of PDGF receptor beta in endocrine pancreatic tumors and metastases compared to normal endocrine pancreas. Acta Oncol 2007;46:741-6
   PubMed Web of Science ®Google Scholar
• Moreno A, Akcakanat A, Munsell MF, Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors. Endocr Relat Cancer 2008;15:257-66
   PubMed Web of Science ®Google Scholar
• Hansel DE, Rahman A, Hermans J, Liver metastases arising from well differentiated pancreatic endocrine neoplasms demonstrate increased VEGF-C expression. Mod Pathol 2003;16:652-9
   PubMed Web of Science ®Google Scholar
• Turner HE, Harris AL, Melmed S, Angiogenesis in endocrine tumors. Endocr Rev 2003;24:600-32
   PubMed Web of Science ®Google Scholar
• Terris B, Scoazec JY, Rubbia L. Expression of vascular endothelial growth factor in digestive neuroendocrine tumors. Histopathology 1998;32:133-8
   PubMed Web of Science ®Google Scholar
• La Rosa S, Uccella S, Finzi G, Localization of vascular endothelial growth factor and its receptors in digestive endocrine tumors: correlation with microvessel density and clinicopathologic features. Hum Pathol 2003;34:18-27
   PubMed Web of Science ®Google Scholar
• Christofori G, Naik P, Hanahan D. Vascular endothelial growth factor and its receptors, flt-1 and flk-1, are expressed in normal pancreatic islets and throughout islet cell tumorigenesis. Mol Endocrinol 1995;9:1760-70
   PubMed Web of Science ®Google Scholar
• Hanahan D. Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus40 oncogenes. Nature 1985;315:115-22
   PubMed Web of Science ®Google Scholar
• Folkman J, Watson K, Ingber D, Hanahan D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 1989;339:58-61
   PubMed Web of Science ®Google Scholar
• Christofori G, Naik P, Hanahan D. Vascular endothelial growth factor and its receptors,flt-1 and flk-1, are expressed in normal pancreatic islets and throughout islet cell tumorigenesis. Mol Endocrinol 1995;9:1760-70
   PubMed Web of Science ®Google Scholar
• Bergers G, Javaherian K, Lo KM, Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 1999;284:808-12
   PubMed Web of Science ®Google Scholar
• Pietras K, Hanahan D. A multitargeted, metronomic, and maximum-tolerated dose ‘chemo-switch' regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J Clin Oncol 2005;23:939-52
   PubMed Web of Science ®Google Scholar
• Mancuso MR, Davis R, Norberg SM, Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest 2006;116:2610-21
   PubMed Web of Science ®Google Scholar
• Paez-Ribes M, Allen E, Hudock J, Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009;15(3):220-31
   PubMed Web of Science ®Google Scholar
• Franco M, Roswall P, Cortez E, Pericytes promote endothelial cell survival through induction of autocrine VEGF-A signaling and Bcl-w expression. Blood 2011;118:2906-17
   PubMed Web of Science ®Google Scholar
• Franco M, Paez-Ribes M, Cortez E, Use of a mouse model of pancreatic neuroendocrine tumors to find pericyte biomarkers of resistance to anti-angiogenic therapy. Horm Metab Res 2011;43:884-9
   PubMed Web of Science ®Google Scholar
• Chiu CW, Nozawa H, Hanahan D. Survival benefit with proapoptotic molecular and pathologic responses from dual targeting of mammalian target of rapamycin and epidermal growth factor receptor in a preclinical model of pancreatic neuroendocrine carcinogenesis. J Clin Oncol 2010;28:4425-33
   PubMed Web of Science ®Google Scholar
• Yao JC, Phan A, Hoff PM, Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon Alfa-2b. J Clin Oncol 2008;26:1316-23
   PubMed Web of Science ®Google Scholar
• Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003;3:401-10
   PubMed Web of Science ®Google Scholar
• Cao Y. Antiangiogenic cancer therapy. Semin Cancer Biol 2004;14:139-45
   PubMed Web of Science ®Google Scholar
• Gerhardt H, Betsholtz C. Endothelial-pericyte interactions in angiogenesis. Cell Tissue Res 2003;314:15-23
   PubMed Web of Science ®Google Scholar
• Pietras K, Sjoblom T, Rubin K, PDGF receptors as cancer drug targets. Cancer Cell 2003;3:439-43
   PubMed Web of Science ®Google Scholar
• Lindahl P, Bostrom H, Karlsson L, Role of platelet-derived growth factors in angiogenesis and alveogenesis. Curr Top Pathol 1999;93:27-33
   PubMedGoogle Scholar
• Abramsson A, Lindblom P, Betsholtz C. Endothelial and non endothelial sources of PDGFB regulate pericyte recruitment and influence vascular pattern formation in tumors. J Clin Invest 2003;112:1142-51
   PubMed Web of Science ®Google Scholar
• Lindblom P, Gerhardt H, Liebner S, Endothelial PDGF-B retention is required for proper investment of pericytes in the microvessel wall. Genes Dev 2003;17:1835-40
   PubMedGoogle Scholar
• Furuhashi M, Sjoblom T, Abramsson A, Platelet-derived growth factor production by B16 melanoma cells leads to increased pericyte abundance in tumors and an associated increase in tumor growth rate. Cancer Res 2004;64:2725-33
   PubMed Web of Science ®Google Scholar
• Benjamin LE, Golijanin D, Itin A, Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 1999;103:159-65
   PubMed Web of Science ®Google Scholar
• Sundberg C, Kowanetz M, Brown LF, Stable expression of angiopoietin-1 and other markers by cultured pericytes: phenotypic similarities to a subpopulation of cells in maturing vessels during later stages of angiogenesis in vivo. Lab Invest 2002;82:387-401
   PubMed Web of Science ®Google Scholar
• Gerhardt H, Wolburg H, Redies C. N-cadherin mediates pericytic-endothelial interaction during brain angiogenesis in the chicken. Dev Dyn 2000;218:472-9
   PubMed Web of Science ®Google Scholar
• Mendel DB, Laird AD, Xin X, In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003;9:327-37
   PubMed Web of Science ®Google Scholar
• Abrams TJ, Lee LB, Murray LJ, SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2003;2:471-8
   PubMed Web of Science ®Google Scholar
• Murray LJ, Abrams TJ, Long KR, SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin Exp Metastasis 2003;20:757-66
   PubMed Web of Science ®Google Scholar
• O'Farrell AM, Abrams TJ, Yuen HA, SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003;101:3597-605
   PubMed Web of Science ®Google Scholar
• Faivre S, Demetri G, Sargent W, Raymond E. Molecular basis for Sunitinib efficacy and future clinical development. Nat Rev Drug Discov 2007;6:734-45
   PubMed Web of Science ®Google Scholar
• Yao J, Sennino B, Davis RB, Combined anti-VEGFR and anti-PDGFR actions of Sunitinib on blood vessels in preclinical tumor models [abstract]. Eur J Cancer 2006;4(Suppl):27-8
   Google Scholar
• Faivre S, Delbaldo C, Vera K, Safety, pharmacokinetic, and antitumor activity of SU11248, novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006;24:25-35
   PubMed Web of Science ®Google Scholar
• Kulke MH, Lenz HJ, Meropol NJ, Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 2008;26:3403-10
   PubMed Web of Science ®Google Scholar
• Raymond E, Dahan L, Raoul JL, Sunitinib Malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011;364:501-13
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Seitz JF, Raoul J, Evaluation of progression-free survival by blinded independent central review in patients with progressive, well-differentiated pancreatic neuroendocrine tumors treated with sunitinib or placebo. ASCO Meeting Abstract; 3 February 2011. p. 249
   Google Scholar
• Missiaglia E, Dalai I, Barbi S, Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway. J Clin Oncol 2010;28:245-55
   PubMed Web of Science ®Google Scholar
• Roldo C, Missiaglia E, Hagan J, MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior. J Clin Oncol 2006;24:4677-84
   PubMed Web of Science ®Google Scholar
• Yao JC, Rindi G, Evans DB. Pancreatic endocrine tumors. In: DeVita VT, Lawrence TS, Rosenberg SA, editors. Cancer: Principles and Practice of Oncology. 8th edition. Wolters Kluwer/Lippincott Williams & Wilkins; Philadelphia: 2008. p. 1702-21
   Google Scholar
• Ferrer-Garcia JC, Tolosa-Torrens M, Hernando-Melia C, Everolimus resolving hypoglycemia, producing hyperglycemia, and necessitating insulin use in a patient with diabetes and non resectable malignant insulinoma. Endocr Pract 2011;17:e17-20
   Web of Science ®Google Scholar
• Wolpin BM, Hezel AF, Abrams T, Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer. J Clin Oncol 2009;27:193-8
   PubMed Web of Science ®Google Scholar
• Kulke MH, Bergsland EK, Yao JC. Glycemic control in patients with insulinoma treated with Everolimus. N Engl J Med 2009;360:195-7
   PubMed Web of Science ®Google Scholar
• Yao JC, Phan AT, Chang DZ, Efficacy of RAD001 (Everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol 2008;26:4311-18
   PubMed Web of Science ®Google Scholar
• Yao JC, Lombard-Bohas C, Baudin E, Daily oral Everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol 2010;28:69-76
   PubMed Web of Science ®Google Scholar
• Yao JC, Shah MH, Ito T, Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011;364:514-23
   PubMed Web of Science ®Google Scholar
• Hobday TJ, Capdevila J, Saletan S, Everolimus in patients with advanced pancreatic neuroendocrine tumors (pNET): Multivariate analysis of progression-free survival from the RADIANT-3 trial. ASCO Meeting Abstracts; 9 June 2011. p. e21091
   Google Scholar
• De Vries E, Anthony LB, Sideris L, Effect of everolimus treatment on chromogranin A, neuron-specific enolase, gastrin, and glucagon levels in patients with advanced pancreatic neuroendocrine tumors (pNET): Phase III RADIANT-3 study results. ASCO Meeting Abstracts; 9 June 2011. p. 10624
   Google Scholar
• Kulke MH, Blaszkowsky L, Zhu A, Phase I/II study of everolimus(RAD001) in combination with temozolomide (TMZ) in patients (pts) with advanced pancreatic neuroendocrine tumors (NET) [abstract]. 2010 Gastrointestinal Cancers Symposium; 2010. p. 127
   Google Scholar
• Kulke MH, Chan JA Bergsland EK. New treatment options for advanced neuroendocrine tumors. ASCO 2011 Educational Book, p. 137-43. Mill Road, Alexandria, VA
   Google Scholar
• Chan JA, Kulke MH. New treatment options for patients with advanced neuroendocrine tumors. Curr Treat Options Oncol 2011;12(2):136-48
   PubMed Web of Science ®Google Scholar
• Oberg K, Castellano D. Current knowledge on diagnosis and staging of neuroendocrine tumors. Cancer Metastasis Rev 2011;30(Suppl 1):3-7
   PubMed Web of Science ®Google Scholar
• Wiedenmann B, Pavel ME, Kos-Kudla B. From targets to treatments: a review of molecular targets in pancreatic neuroendocrine tumors. Neuroendocrinology 2011;94:177-90
   PubMed Web of Science ®Google Scholar
• Pavel ME, Wiedenmann B. Novel therapeutic agents for the treatment of gastroenteropancreatic neuroendocrine tumors. Horm Metab Res 2011;43:844-53
   PubMed Web of Science ®Google Scholar
• Oberg K. Pancreatic endocrine tumors. Semin Oncol 2010;37:594-618
   PubMed Web of Science ®Google Scholar
• Jensen RT, Delle Fave G. Promising advances in the treatment of malignant pancreatic endocrine tumors. Editorial. N Engl J Med 2011;364:564-5
   PubMed Web of Science ®Google Scholar
• Yao JC, Phan A, Hoff PM, Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alfa-2b. J Clin Oncol 2008;26:1316-23
   PubMed Web of Science ®Google Scholar
• Kulke MH, Lenz HJ, Meropol NJ, Activity of sunitnib in patients with advanced neuroendocrine tumors. J Clin Oncol 2008;26:3403-10
   PubMed Web of Science ®Google Scholar
• Hobday TJ, Rubin J, Holen K, MC044h, a phase II trial of sorafenib in patients (pts) with metastatic neuroendocrine tumors (NET): a phase II consortium (P2C) study. J Clin Oncol 2007;25(18s suppl):abstract 4505
   Google Scholar
• Phan A, Yao JC, Fogelman D, A prospective, multi-institutional phase II study of GW786034 (pazopanib) and depot octreotide (sandostatin LAR) in advanced low-grade neuroendocrine carcinoma (LGNEC). J Clin Oncol 2010;28(18s suppl):abstract 4044
   Google Scholar
• Gross DJ, Munter G, Bitan M, The role of imatinib mesylate (Glivec) for treatment of patients with malignant endocrine tumors positive for c-kit or PDGF-R. Endocr Relat Cancer 2006;13:535-40
   PubMed Web of Science ®Google Scholar
• Pavel ME, Bartel C, Heuck F, Open-label, non-randomized, multicenter phase II study evaluating the angiogenesis inhibitor PTK787/ZK222584 (PTK/ZK) in patients with advanced neuroendocrine carcinomas (NEC). J Clin Oncol 2008;26:abstract
   Web of Science ®Google Scholar
• Hobday TJ, Holen K, Donehower R, A phase II trial of gefitinib in patients (pts)with progressive metastatic neuroendocrine tumors (NET): a Phase II Consortium (P2C) study. J Clin Oncol 2006;24:abstract
   Web of Science ®Google Scholar
• Yao JC, Phan A, Hoff PM, Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol 2008;26:1316-23
   PubMed Web of Science ®Google Scholar
• Yao JC, Lombard-Bohas C, Baudin E, Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol 2010;28:69-76
   PubMed Web of Science ®Google Scholar
• Duran I, Kortmansky J, Singh D, A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. Br J Cancer 2006;6:1148-54
   Google Scholar
• Panzuto F, Di Fonzo M, Iannicelli E, Long-term clinical outcome of somatostatin analogues for treatment of progressive, metastatic, well-differentiated entero-pancreatic endocrine carcinoma. Ann Oncol 2006;17:461-6
   PubMed Web of Science ®Google Scholar
• Kwekkeboom DJ, de Herder WW, Kam BL, Treatment with theradiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol 2008;26:2124-30
   PubMed Web of Science ®Google Scholar
• Moertel CG, Lefkopoulo M, Lipsitz S, Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet cell carcinoma. N Engl J Med 1992;326:519-23
   PubMed Web of Science ®Google Scholar
• Ramanathan RK, Cnaan A, Hahn RG, Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. Study of the Eastern Cooperative Oncology Group-E6282. Ann Oncol 2001;12:1139-43
   PubMed Web of Science ®Google Scholar
• Kulke MH, Stuart K, Enzinger PC, Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol 2006;24:401-6
   PubMed Web of Science ®Google Scholar
• Kulke MH, Stuart K, Earle C, A phase II study of temozolomide and bevacizumab in patients with advanced neuroendocrine tumors. J Clin Oncol 2006;24(18s suppl):abstract 4044
   Google Scholar
• Kulke MH, Blaszkowsky L, Zhu A, Phase I/II study of everolimus(RAD001) in combination with temozolomide (TMZ) in patients (pts) with advanced pancreatic neuroendocrine tumors (NET) [abstract]. 2010 Gastrointestinal Cancers Symposium; 2010. p. 127
   Google Scholar
• Kouvaraki MA, Ajani JA, Hoff P, Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol 2004;22:4762-71
   PubMed Web of Science ®Google Scholar
• Kulke M, Hornick J, Frauenhoffer C, O6-methylguanine DNAmethyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. Clin Cancer Res 2009;15:338-45
   PubMed Web of Science ®Google Scholar
• Ekeblad S, Sundin A, Janson ET, Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin Cancer Res 2007;13:2986-91
   PubMed Web of Science ®Google Scholar
• Strosberg JR, Fine RL, Choi J, First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer 2010;117:268-75
   PubMed Web of Science ®Google Scholar
• Pavel ME, Hainsworth JD, Baudin E, Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase III study. Lancet 2011;378:2005-12
   PubMed Web of Science ®Google Scholar